Apotex Strengthens Osteoporosis Care in Canada with Health Canada's Approval of DENOZA™, a Denosumab Biosimilar
Apr 7, 2026Toronto, ON – April 7, 2026 – Apotex Inc. ("Apotex" or the "Company"), the largest Canadian based global pharmaceutical company, today announced that Health Canada has approved DENOZA™ (denosumab injection), a biosimilar to Prolia®, for its authorized indications. These include the treatment of postmenopausal women with osteoporosis at high risk for fracture and the treatment of osteoporosis in men at high risk for fracture1. DENOZA is also authorized for the remaining indications of the reference biologic, as outlined in the Product Monograph. The product will be available in a prefilled syringe format.
"As a Force for Health, focusing on patient access to appropriate treatment options is a core part of our mission," said Martin Arès, President, Apotex Canada and Rest of World. "Osteoporosis is a significant public health issue, affecting more than 2.3 million Canadians2. The approval of DENOZA reflects our continued commitment to helping improve access to treatment options and contributing to a sustainable healthcare system, while offering healthcare professionals and patients additional choices in care."
Dr. Angela M. Cheung, Professor of Medicine, KY and Betty Ho Chair in Integrative Medicine, University of Toronto, Senior Physician Scientist at University Health Network, and Founding Director of the University Health Network Osteoporosis Program, added: "Timely access to osteoporosis therapies plays an important role in supporting patient care and helping reduce the impact of this underdiagnosed condition. The introduction of additional treatment options, including biosimilars such as DENOZA, can support healthcare providers and patients by broadening available choices within the current treatment landscape."
Dr. Famida Jiwa, President and CEO of Osteoporosis Canada, also welcomed the approval, noting: "Expanding access to therapies is an important step in supporting Canadians living with osteoporosis. The approval of DENOZA adds another option to the range of treatments available within the healthcare system."
Healthcare professionals should refer to the complete Product Monograph for detailed information on warnings, precautions, adverse reactions, and patient monitoring requirements.
About Apotex
Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals, and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions.
Learn more about us at www.apotex.com.
1 Product Monograph: https://pdf.hres.ca/dpd_pm/00083929.PDF
2 Osteoporosis Canada. Facts and Statistics: https://osteoporosis.ca/facts-and-stats/
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Sep 18, 2026
Apotex Health Corp. announces closing of upsized bought deal secondary offering
Toronto, Ontario, September 18, 2026 – Apotex Health Corp. ("Apotex" or the "Company") announced today the closing of the previously announced upsized secondary offering (the "Offering") of common shares of the Company (the "Common Shares") by an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders").
-
Sep 15, 2026
Apotex Health Corp. announces upsize of bought deal secondary offering to $850 million
Toronto, Ontario, September 15, 2026 - Apotex Health Corp. ("Apotex" or the "Company") announced today that, as a result of strong demand, Apotex, an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders") have entered into an amended agreement with the syndicate of underwriters (the "Underwriters") led by RBC Capital Markets, TD Securities Inc., and Scotiabank, as joint lead bookrunners, and BMO Capital Markets and Jefferies Securities, Inc., as joint bookrunners, to increase the size of the previously announced bought deal secondary offering of common shares of the Company (the "Common Shares"). Under the amended agreement, the Underwriters have agreed to purchase 25,000,000 Common Shares from the Selling Shareholders at a purchase price of $34.00 per Common Share for total gross proceeds of approximately $850,000,000 (the "Upsized Offering").
-
Sep 15, 2026
Apotex Health Corp. announces $750 million bought deal secondary offering
Toronto, Ontario, September 14, 2026 - Apotex Health Corp. ("Apotex" or the "Company") announced today that Apotex, an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders") have entered into an agreement with a syndicate of underwriters (the "Underwriters") led by RBC Capital Markets, TD Securities Inc., and Scotiabank, as joint lead bookrunners, and BMO Capital Markets and Jefferies Securities, Inc., as joint bookrunners, to complete a secondary offering on a bought deal basis (the "Offering") of common shares of the Company (the "Common Shares"). Under the agreement, the Underwriters have agreed to purchase 22,058,825 Common Shares from the Selling Shareholders at a purchase price of $34.00 per Common Share for total gross proceeds of approximately $750,000,050.